
MSL-醫(yÄ«)å¸(xué)è¯(lián)絡(luò)官

è·ä½æè¿°
è·ä½æè¿°ï¼š
Key Accountabilities/Responsibilities主è¦å·¥ä½œè·è²¬(zé):
1 MSL works under TA physician to establish, build and manage relationships with identified HCPs.
2 MSL acts as a field-based expert and should develop and maintain extensive knowledge on CVM/CNS in order to serve as a scientific resource.
3 MSL should responsibly interact, educate and engage identified HCPs to raise disease awareness on relevant disease to meet the scientific needs of HCPs
4 MSL should investigate on avenues where scientific information on the disease is needed and support opportunities with HCPs within the scope of their scientific focus.
5 MSL acts as a conduit with the in-house physician and Medical Affairs Head, and engage in disease related conversations with HCPs with supportive science materials approved by Area Medical Director.
6 Each MSL supports an acceptable number of HCPs in their assigned territories.
7 MSL interacts with HCPs, and discuss:
7.1 Discussions on disease awareness
7.2 Responding to unsolicited requests for educational materials
7.3 Relevant scientific interest
8 In general, a sales representative will not be involved in meetings between HCPs and MSL unless the sales representative is introducing the MSL for an initial meeting.
Qualifications/Requirements: (Education / Experience / Competencies)
申請(qÇng)è³‡æ ¼ / è·ä½è¦æ±‚:(教育背景 / 工作經(jÄ«ng)é©—(yà n) / 知è˜(shÃ)與技能)
Knowledge & Experience Skills
? Master’s Degree in medicine, with a minimum of 2 years’ experience in hospital
? Ability to deliver effective presentations, facilitate group discussions, communicate and interact with a diverse group of individuals
? Good command of English (written and spoken);
? Knowledge of PC (WORD, EXCEL, POWERPOINT);
? Interpersonal communication skill;
? Team player
? Presentation skill
? Project Management
伿¥(yè)ç°¡(jiÇŽn)介
GlaxoSmithkline/è‘›è˜ç´ å²å…‹
ä½œç‚ºä¸–ç•Œé ˜(lÇng)先的制藥æ¥(yè)巨擘,葛è˜ç´ å²å…‹å…¬å¸ç§‰æ‰¿ä»¥ç ”ç©¶é–‹(kÄi)發(fÄ)為基礎(chÇ”)的一貫ç†å¿µï¼Œæ†‘è—‰å…¬å¸æœ¬èº«çš„æŠ€è¡“(shù)潛力和資æºå„ª(yÅu)å‹¢(shì),在當(dÄng)今瞬æ¯è¬(wà n)變的醫(yÄ«)療ä¿å¥é ˜(lÇng)åŸŸä¿æŒå¼·(qiáng)å‹çš„增長(zhÇŽng)å‹¢(shì)é 。
è‘›è˜ç´ å²å…‹å…¬å¸ï¼Œç”±è‘›è˜ç´ å¨åº·å’Œå²å…‹å¿…æˆå¼·(qiáng)å¼·(qiáng)è¯(lián)åˆï¼ŒäºŽ2000å¹´12月æˆç«‹ã€‚å…©å®¶å…¬å¸çš„æ·å²å‡å¯è¿½æº¯è‡³19世紀(jì)ä¸è‘‰ï¼Œå„自在一個(gè)多世紀(jì)çš„ä¸æ–·å‰µ(chuà ng)新和數(shù)次åˆå¹¶ä¸ï¼Œåœ¨é†«(yÄ«)è—¥é ˜(lÇng)域都確立了世界級(jÃ)çš„é ˜(lÇng)先地ä½ã€‚兩個(gè)制藥巨人的æˆåŠŸåˆå¹¶ï¼Œç‚ºè‘›è˜ç´ å²å…‹æˆç‚ºè¡Œæ¥(yè)ä¸ç„¡(wú)å¯çˆ(zhÄ“ng)è°çš„é ˜(lÇng)å°Ž(dÇŽo)è€…å¥ å®šäº†åŸºç¤Ž(chÇ”),并在全çƒè—¥å“å¸‚å ´(chÇŽng)ä¸å 據(jù)有7%的份é¡ã€‚
è‘›è˜ç´ å²å…‹å…¬å¸ç¸½éƒ¨è¨(shè)在英國(guó),以美國(guó)為æ¥(yè)å‹™(wù)營(yÃng)é‹(yùn)ä¸å¿ƒï¼Œåœ¨æŠ—感染ã€ä¸æ¨žç¥žç¶“(jÄ«ng)系統(tÇ’ng)ã€å‘¼å¸å’Œèƒƒè…¸é“/代è¬å››å¤§é†«(yÄ«)ç™‚é ˜(lÇng)域代表當(dÄng)ä»Šä¸–ç•Œçš„æœ€é«˜æ°´å¹³ï¼Œåœ¨ç–«è‹—é ˜(lÇng)域雄居行æ¥(yè)榜首。æ¤å¤–,公å¸åœ¨æ¶ˆè²»(fèi)ä¿å¥é ˜(lÇng)åŸŸä¹Ÿå±…ä¸–ç•Œé ˜(lÇng)先地ä½ï¼Œä¸»è¦ç”¢(chÇŽn)å“包括éžè™•方藥ã€å£è…”è·(hù)ç†å“和營(yÃng)養(yÇŽng)ä¿å¥é£²æ–™ã€‚2006å¹´å…¬å¸åœ¨å…¨çƒçš„銷售總é¡é”(dá)232億英鎊。目å‰ï¼Œå…¬å¸åœ¨å…¨çƒæ“有10è¬(wà n)余志¢æŽŒæ¡å°ˆæ¥(yè)æŠ€èƒ½åˆæœ‰å¥‰ç»(xià n)精神的出色員工。
å…¨çƒç ”發(fÄ)ä¸å¿ƒæœ‰1è¬(wà n)6åƒç§‘å¸(xué)家和技術(shù)人員分布在全çƒè¨±å¤šåœ‹(guó)家。為進(jìn)ä¸€æ¥æŽ¨å‹•(dòng)ç ”ç™¼(fÄ)å…¨çƒåŒ–,葛è˜ç´ å²å…‹ï¼ˆGSK)ä¸åœ‹(guó)ç ”ç™¼(fÄ)ä¸å¿ƒäºŽ2007å¹´6月æˆç«‹ã€‚ä¸å¿ƒå°‡å´(cè)é‡äºŽç¥žç¶“(jÄ«ng)é€€è¡Œæ€§ç—…è®Šçš„ç ”ç©¶ï¼Œç›®æ¨™(biÄo)是為多發(fÄ)性硬化病ã€å¸•金森病和阿爾茨海默æ°ç—…ç‰åš´(yán)é‡ç–¾ç—…é–‹(kÄi)發(fÄ)新藥。ä¸åœ‹(guó)ç ”ç™¼(fÄ)ä¸å¿ƒå°‡ç™¼(fÄ)å±•æˆæœ‰1000多科å¸(xué)家和技術(shù)人員的全çƒç ”發(fÄ)ä¸å¿ƒã€‚ä¸å¿ƒå°‡ä»¥ç§‘å¸(xué)ç ”ç©¶ç‚ºåŸºç¤Ž(chÇ”)(science-driven),通éŽ(guò)生物å¸(xué),化å¸(xué)ä»¥åŠæœ€æ–°æŠ€è¡“(shù),創(chuà ng)æ–°é–‹(kÄi)發(fÄ)新的治療手段。ä¸åœ‹(guó)ç ”ç™¼(fÄ)ä¸å¿ƒå°‡æœ€çµ‚å¼•é ˜(lÇng)GSKåœ¨é€™ä¸€é ˜(lÇng)域從è˜(shÃ)åˆ¥è—¥ç‰©é¶æ¨™(biÄo)åˆ°åŽæœŸè‡¨åºŠç ”究的全çƒç ”發(fÄ)活動(dòng),并在ä¸åœ‹(guó)å’Œå…¶ä»–ç ”ç©¶æ©Ÿ(jÄ«)æ§‹(gòu)密切åˆä½œã€‚GSKä¸åœ‹(guó)ç ”ç™¼(fÄ)ä¸å¿ƒè¨ˆ(jì)劃在未來(lái)10å¹´å…§(nèi)æˆé•·(zhÇŽng)為GSKçš„å¤§åž‹ç ”ç™¼(fÄ)ä¸å¿ƒä¹‹ä¸€ã€‚
更多信æ¯è«‹(qÇng)?jiÄn)Lå•(wèn)我們的網(wÇŽng)站。
è·ä½ç™¼(fÄ)å¸ƒä¼æ¥(yè)

è‘›è˜ç´ å²å…‹ï¼ˆä¸åœ‹(guó))投資有é™å…¬å¸
伿¥(yè)性質(zhì)ï¼šå¤–è³‡ä¼æ¥(yè)
伿¥(yè)è¦(guÄ«)模:1000-1999人
æˆç«‹å¹´ä»½ï¼š2000
伿¥(yè)ç¶²(wÇŽng)å€ï¼šhttp://www.gsk-china.com/chinese/
伿¥(yè)地å€ï¼šä¸Šæµ·